Lineage Cell Therapeutics
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
Revenue | $3,681 | $2,765 | $1,502 | $2,868 |
Gross Profit | 3,676 | 2,726 | 1,466 | 2,714 |
EBITDA | -29,574 | -4,769 | -6,341 | -4,959 |
EBIT | -29,752 | -4,940 | -6,505 | -5,110 |
Net Income | -29,781 | -30,464 | -4,139 | -3,273 |
Net Change In Cash | 3,681 | 2,765 | 1,502 | 2,868 |
Free Cash Flow | -3,628 | -5,553 | -4,983 | -6,711 |
Cash | 40,463 | 42,271 | 47,886 | 45,789 |
Basic Shares | 228,853 | 228,356 | 226,054 | 200,193 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $9,499 | $8,945 | $14,703 | $3,896 |
Gross Profit | 9,165 | 8,274 | 13,975 | 2,470 |
EBITDA | -20,869 | -24,041 | -21,793 | -48,338 |
EBIT | -21,478 | -24,733 | -22,520 | -49,211 |
Net Income | -18,609 | -21,486 | -26,273 | -43,019 |
Net Change In Cash | 9,499 | 8,945 | 14,703 | 3,896 |
Cost of Revenue | -43,468 | 23,114 | ||
Free Cash Flow | -23,657 | -29,240 | 646 | -23,915 |
Cash | 45,789 | 35,442 | 11,355 | 55,742 |
Basic Shares | 200,193 | 172,663 | 169,792 | 164,502 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-12-31 | $0 |
2025-09-30 | -$0.13 |
2025-06-30 | -$0.13 |
2025-03-31 | -$0.02 |
